5:18 PM
May 18, 2017
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Lorediplon meets in Phase II insomnia trial

In February, Ergomed plc (LSE:ERGO) said 5 and 10 mg oral lorediplon each met the primary endpoint in a Phase II trial to treat insomnia. Specifically, low- and high-dose lorediplon significantly reduced mean Wake After Sleep Onset (WASO) throughout the night as measured by polysomnography vs. placebo (improvements of 19 and 23 minutes compared to placebo, respectively, p<0.0001 for...

Read the full 271 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >